A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 21,311 shares of PCVX stock, worth $1.85 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
21,311
Previous 21,311 -0.0%
Holding current value
$1.85 Million
Previous $2.43 Million -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$70.52 - $117.12 $58,249 - $96,741
826 Added 4.03%
21,311 $2.43 Million
Q2 2024

Jul 29, 2024

BUY
$60.06 - $78.77 $128,468 - $168,489
2,139 Added 11.66%
20,485 $1.55 Million
Q1 2024

Apr 25, 2024

BUY
$59.79 - $81.05 $71,329 - $96,692
1,193 Added 6.96%
18,346 $1.25 Million
Q4 2023

Jan 30, 2024

BUY
$45.35 - $63.41 $282,485 - $394,980
6,229 Added 57.02%
17,153 $1.08 Million
Q3 2023

Oct 25, 2023

BUY
$46.0 - $53.1 $56,718 - $65,472
1,233 Added 12.72%
10,924 $556,000
Q2 2023

Aug 07, 2023

BUY
$34.66 - $54.07 $51,262 - $79,969
1,479 Added 18.01%
9,691 $483,000
Q1 2023

May 08, 2023

BUY
$36.27 - $47.2 $28,943 - $37,665
798 Added 10.76%
8,212 $307,000
Q4 2022

Feb 01, 2023

BUY
$20.58 - $47.95 $11,072 - $25,797
538 Added 7.82%
7,414 $355,000
Q3 2022

Nov 09, 2022

BUY
$21.69 - $28.53 $43,640 - $57,402
2,012 Added 41.37%
6,876 $165,000
Q2 2022

Aug 09, 2022

SELL
$17.68 - $26.58 $1,803 - $2,711
-102 Reduced 2.05%
4,864 $106,000
Q1 2022

Apr 21, 2022

BUY
$17.46 - $26.36 $86,706 - $130,903
4,966 New
4,966 $120,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.15B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.